Timapiprant
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526810

CAS#: 851723-84-7 (free acid)

Description: Timapiprant, also known as OC000459, is a potent, selective and orally active CRTH2 antagonist. OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. OC000459 inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. OC000459 treatment inhibited LAR and post-allergen increase in sputum eosinophils. OC000459 appears to inhibit allergic inflammation in asthma.


Chemical Structure

img
Timapiprant
CAS# 851723-84-7 (free acid)

Theoretical Analysis

MedKoo Cat#: 526810
Name: Timapiprant
CAS#: 851723-84-7 (free acid)
Chemical Formula: C21H17FN2O2
Exact Mass: 348.13
Molecular Weight: 348.377
Elemental Analysis: C, 72.40; H, 4.92; F, 5.45; N, 8.04; O, 9.18

Price and Availability

Size Price Availability Quantity
100mg USD 1050
200mg USD 1750
500mg USD 2450
1g USD 3250
2g USD 5450
5g USD 7650
Bulk inquiry

Related CAS #: 851723-84-7 (free acid)   950688-14-9 (sodium),  

Synonym: OC000459; OC-000459; OC 000459; Timapiprant.

IUPAC/Chemical Name: 2-(5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)-1H-indol-1-yl)acetic acid

InChi Key: FATGTHLOZSXOBC-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H17FN2O2/c1-13-17(11-16-8-6-14-4-2-3-5-19(14)23-16)18-10-15(22)7-9-20(18)24(13)12-21(25)26/h2-10H,11-12H2,1H3,(H,25,26)

SMILES Code: O=C(O)CN1C(C)=C(CC2=NC3=CC=CC=C3C=C2)C4=C1C=CC(F)=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 348.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bielory L, Schoenberg D. Ocular allergy: update on clinical trials. Curr Opin Allergy Clin Immunol. 2019 Oct;19(5):495-502. doi: 10.1097/ACI.0000000000000564. PubMed PMID: 31465314.

2: Yanes DA, Mosser-Goldfarb JL. Emerging therapies for atopic dermatitis: The prostaglandin/leukotriene pathway. J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S71-S75. doi: 10.1016/j.jaad.2017.12.021. Epub 2017 Dec 15. Review. PubMed PMID: 29248523.

3: Kupczyk M, Kuna P. Targeting the PGD(2)/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives. Drugs. 2017 Aug;77(12):1281-1294. doi: 10.1007/s40265-017-0777-2. Review. PubMed PMID: 28612233; PubMed Central PMCID: PMC5529497.

4: Otani IM, Nadeau KC. Biologic Therapies for Immunoglobulin E-mediated Food Allergy and Eosinophilic Esophagitis. Immunol Allergy Clin North Am. 2017 May;37(2):369-396. doi: 10.1016/j.iac.2017.01.010. Review. PubMed PMID: 28366483.

5: Santini G, Mores N, Malerba M, Mondino C, Macis G, Montuschi P. Investigational prostaglandin D2 receptor antagonists for airway inflammation. Expert Opin Investig Drugs. 2016 Jun;25(6):639-52. doi: 10.1080/13543784.2016.1175434. Epub 2016 Apr 25. Review. PubMed PMID: 27094922.

6: McIvor RA. Emerging therapeutic options for the treatment of patients with symptomatic asthma. Ann Allergy Asthma Immunol. 2015 Oct;115(4):265-271.e5. doi: 10.1016/j.anai.2015.07.011. Epub 2015 Aug 5. Review. PubMed PMID: 26254973.

7: Pettipher R, Hunter MG, Perkins CM, Collins LP, Lewis T, Baillet M, Steiner J, Bell J, Payton MA. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014 Sep;69(9):1223-32. doi: 10.1111/all.12451. Epub 2014 Jul 14. PubMed PMID: 24866478.

8: Straumann A, Hoesli S, Bussmann Ch, Stuck M, Perkins M, Collins LP, Payton M, Pettipher R, Hunter M, Steiner J, Simon HU. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013 Mar;68(3):375-85. doi: 10.1111/all.12096. Epub 2013 Feb 5. PubMed PMID: 23379537.

9: Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Collins LP, Hunter MG, Steiner J, Lewis T, Payton MA, Perkins CM, Pettipher R. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012 Dec;67(12):1572-9. doi: 10.1111/all.12042. Epub 2012 Oct 1. PubMed PMID: 23025511.

10: Singh D, Cadden P, Hunter M, Pearce Collins L, Perkins M, Pettipher R, Townsend E, Vinall S, O'Connor B. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013 Jan;41(1):46-52. doi: 10.1183/09031936.00092111. Epub 2012 Apr 10. PubMed PMID: 22496329.

11: Pettipher R, Vinall SL, Xue L, Speight G, Townsend ER, Gazi L, Whelan CJ, Armer RE, Payton MA, Hunter MG. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther. 2012 Feb;340(2):473-82. doi: 10.1124/jpet.111.187203. Epub 2011 Nov 21. PubMed PMID: 22106101.

12: Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis T, Parker D, Payton M, Collins LP, Pettipher R, Steiner J, Perkins CM. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy. 2012 Jan;42(1):38-48. doi: 10.1111/j.1365-2222.2011.03813.x. Epub 2011 Jul 15. PubMed PMID: 21762224.